hydroxychloroquine has been researched along with Diabetes Mellitus, Adult-Onset in 39 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of hydroxychloroquine (HCQ) on skeletal muscle and liver insulin sensitivity, insulin clearance, inflammation and adipokines." | 9.41 | The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial. ( DeLany, JP; Helbling, NL; Miller, RG; Toledo, FGS; Zhang, Y, 2021) |
| "Observational studies suggest that hydroxychloroquine (HCQ) may reduce the risk of developing diabetes mellitus in patients with rheumatoid arthritis (RA)." | 9.19 | Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. ( Garg, R; Lu, B; Massarotti, E; Mercer, E; Norton, T; Solomon, DH; Todd, DJ, 2014) |
| "This review examines the pharmacokinetics, modes of action and therapeutic properties of the anti-malarial drugs, hydroxychloroquine (HCQ) and chloroquine (CQ), in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and related conditions, as well as osteoarthritis (OA)." | 8.91 | Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. ( Clifford-Rashotte, M; Kean, WF; Parke, AL; Rainsford, KD, 2015) |
| "The study was conducted to investigate the effects of hydroxychloroquine, an anti-inflammatory drug, which was recently approved and used as an add on oral antidiabetic drug for uncontrolled Type 2 Diabetes Mellitus (DM) on an adequate dose of sulfonylurea and metformin on the progression of diabetic retinopathy (DR) in subjects with Rheumatoid Arthritis and Type 2 Diabetes Mellitus." | 8.12 | Effects of Hydroxychloroquine on Progression of Diabetic Retinopathy in Subjects with Rheumatoid Arthritis and Type 2 Diabetes Mellitus. ( Baidya, A, 2022) |
| "Several studies have associated hydroxychloroquine use with decreased risk of diabetes mellitus (diabetes) or improved glycemic control in rheumatoid arthritis patients, but the studies were small or used data from self-report." | 7.77 | Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. ( Antohe, JL; Bili, A; Dancea, S; Kirchner, HL; Ledwich, LJ; Morris, SJ; Newman, ED; Sartorius, JA; Wasko, MC, 2011) |
| "To determine the effect of hydroxychloroquine (HCQ) on skeletal muscle and liver insulin sensitivity, insulin clearance, inflammation and adipokines." | 5.41 | The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial. ( DeLany, JP; Helbling, NL; Miller, RG; Toledo, FGS; Zhang, Y, 2021) |
| "Hydroxychloroquine has been reported to reduce insulin requirements in refractory type II diabetes by an average of 30%." | 5.30 | Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. ( Elliott, T; Koehler, BE; Shojania, K, 1999) |
| "Observational studies suggest that hydroxychloroquine (HCQ) may reduce the risk of developing diabetes mellitus in patients with rheumatoid arthritis (RA)." | 5.19 | Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. ( Garg, R; Lu, B; Massarotti, E; Mercer, E; Norton, T; Solomon, DH; Todd, DJ, 2014) |
| "This review examines the pharmacokinetics, modes of action and therapeutic properties of the anti-malarial drugs, hydroxychloroquine (HCQ) and chloroquine (CQ), in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and related conditions, as well as osteoarthritis (OA)." | 4.91 | Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. ( Clifford-Rashotte, M; Kean, WF; Parke, AL; Rainsford, KD, 2015) |
| "The study was conducted to investigate the effects of hydroxychloroquine, an anti-inflammatory drug, which was recently approved and used as an add on oral antidiabetic drug for uncontrolled Type 2 Diabetes Mellitus (DM) on an adequate dose of sulfonylurea and metformin on the progression of diabetic retinopathy (DR) in subjects with Rheumatoid Arthritis and Type 2 Diabetes Mellitus." | 4.12 | Effects of Hydroxychloroquine on Progression of Diabetic Retinopathy in Subjects with Rheumatoid Arthritis and Type 2 Diabetes Mellitus. ( Baidya, A, 2022) |
| "Several studies have associated hydroxychloroquine use with decreased risk of diabetes mellitus (diabetes) or improved glycemic control in rheumatoid arthritis patients, but the studies were small or used data from self-report." | 3.77 | Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. ( Antohe, JL; Bili, A; Dancea, S; Kirchner, HL; Ledwich, LJ; Morris, SJ; Newman, ED; Sartorius, JA; Wasko, MC, 2011) |
| "Hydroxychloroquine (HCQ) is a widely used antimalarial and anti-inflammatory drug and its hyperglycemia-controlling effect in diabetic patients is also under investigation." | 3.01 | Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19? ( Das, A; Koka, S; Kukreja, RC; Samidurai, A; Wang, R; Xi, L, 2023) |
| "Hydroxychloroquine was associated with significant reduction in HbA1c from baseline (7-8." | 3.01 | Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs. ( Chakravarti, HN; Nag, A, 2021) |
| "Hydroxychloroquine is an immunomodulatory drug that has been used for the treatment of malaria and autoimmune diseases." | 2.66 | Potential Effect of Hydroxychloroquine in Diabetes Mellitus: A Systematic Review on Preclinical and Clinical Trial Studies. ( Adamu, BA; Desalegn, TZ; Tsige, AG; Wondafrash, DZ; Yimer, EM; Zewdie, KA, 2020) |
| " In conclusion, the CQ dosage and regimen used to treat COVID-19 induced adverse effects in diabetic rats, suggesting the need to reevaluate the effective dose of CQ in humans." | 1.72 | Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19. ( Gao, X; Guo, D; Ji, H; Jiang, S; Jing, X; Peng, L; Qiu, Y; Wang, J; Wu, W; Zheng, Y, 2022) |
| "Treatment with hydroxychloroquine might not be enough to lower the cardiovascular risk significantly in diabetes patients with Sjögren syndrome." | 1.72 | Sjögren syndrome is a hidden contributor of macrovascular and microvascular complications in patients with type 2 diabetes. ( Leong, PY; Su, YJ; Wang, YH; Wei, JC, 2022) |
| "The worldwide incidence of coronavirus disease 2019 (COVID-19) infection is rapidly increasing, but there exists limited information on coronavirus disease 2019 in pregnancy." | 1.56 | Coronavirus disease 2019 in pregnancy: early lessons. ( Baptiste, C; Breslin, N; D'Alton, M; Fuchs, K; Goffman, D; Gyamfi-Bannerman, C; Miller, R, 2020) |
| "A chest CT scan showed an acute type B aortic dissection (ATBAD) and bilateral lung involvement with ground-glass opacity, compatible with interstitial pneumonia." | 1.56 | An infection-oriented approach for thoracic endovascular aortic repair in a SARS-CoV-2 positive patient. A case report. ( Ferrari, SA; Muzzarelli, L; Piconi, S; Rossi, G; Sommaruga, S, 2020) |
| "Hydroxychloroquine and abatacept were associated with decreased risk of DM, and glucocorticoids and statins with increased risk." | 1.46 | Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. ( Avery, M; Holmqvist, ME; Michaud, K; Ozen, G; Pedro, S; Wolfe, F, 2017) |
| "Hydroxychloroquine has been reported to reduce insulin requirements in refractory type II diabetes by an average of 30%." | 1.30 | Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. ( Elliott, T; Koehler, BE; Shojania, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.13) | 18.2507 |
| 2000's | 3 (7.69) | 29.6817 |
| 2010's | 17 (43.59) | 24.3611 |
| 2020's | 17 (43.59) | 2.80 |
| Authors | Studies |
|---|---|
| Baidya, A | 1 |
| Gao, X | 1 |
| Jing, X | 1 |
| Wang, J | 1 |
| Zheng, Y | 1 |
| Qiu, Y | 1 |
| Ji, H | 1 |
| Peng, L | 1 |
| Jiang, S | 1 |
| Wu, W | 1 |
| Guo, D | 1 |
| Mikkelsen, RR | 1 |
| Hundahl, MP | 1 |
| Torp, CK | 1 |
| Rodríguez-Carrio, J | 1 |
| Kjolby, M | 1 |
| Bruun, JM | 1 |
| Kragstrup, TW | 1 |
| Su, YJ | 1 |
| Leong, PY | 2 |
| Wang, YH | 2 |
| Wei, JC | 2 |
| Kukreja, RC | 1 |
| Wang, R | 1 |
| Koka, S | 1 |
| Das, A | 1 |
| Samidurai, A | 1 |
| Xi, L | 1 |
| Sharma, M | 1 |
| Kumar, M | 1 |
| Dutta, D | 1 |
| Hsia, SH | 1 |
| Duran, P | 1 |
| Lee, ML | 1 |
| Davidson, MB | 1 |
| Gupta, A | 1 |
| Wondafrash, DZ | 1 |
| Desalegn, TZ | 1 |
| Yimer, EM | 1 |
| Tsige, AG | 1 |
| Adamu, BA | 1 |
| Zewdie, KA | 1 |
| Infante, M | 1 |
| Ricordi, C | 1 |
| Fabbri, A | 1 |
| Breslin, N | 1 |
| Baptiste, C | 1 |
| Miller, R | 1 |
| Fuchs, K | 1 |
| Goffman, D | 1 |
| Gyamfi-Bannerman, C | 1 |
| D'Alton, M | 1 |
| Chakravarti, HN | 1 |
| Nag, A | 1 |
| Azmy, V | 1 |
| Benson, J | 1 |
| Love, K | 1 |
| Steele, R | 1 |
| Rein, N | 1 |
| Haham, N | 1 |
| Orenbuch-Harroch, E | 1 |
| Romain, M | 1 |
| Argov, Z | 1 |
| Vaknin-Dembinsky, A | 1 |
| Gotkine, M | 1 |
| Rossi, G | 1 |
| Ferrari, SA | 1 |
| Sommaruga, S | 1 |
| Muzzarelli, L | 1 |
| Piconi, S | 1 |
| Croft, A | 1 |
| Bucca, A | 1 |
| Jansen, JH | 1 |
| Motzkus, C | 1 |
| Herbert, A | 1 |
| Wang, A | 1 |
| Hunter, BR | 1 |
| Toledo, FGS | 1 |
| Miller, RG | 1 |
| Helbling, NL | 1 |
| Zhang, Y | 1 |
| DeLany, JP | 1 |
| Chen, HC | 1 |
| Lin, HY | 1 |
| Chou, MC | 1 |
| Marchetti, M | 1 |
| Baker, MG | 1 |
| Noland, MM | 1 |
| Solomon, DH | 1 |
| Garg, R | 1 |
| Lu, B | 1 |
| Todd, DJ | 1 |
| Mercer, E | 1 |
| Norton, T | 1 |
| Massarotti, E | 1 |
| Pareek, A | 3 |
| Chandurkar, N | 2 |
| Thomas, N | 1 |
| Viswanathan, V | 1 |
| Deshpande, A | 1 |
| Gupta, OP | 1 |
| Shah, A | 1 |
| Kakrani, A | 1 |
| Bhandari, S | 1 |
| Thulasidharan, NK | 1 |
| Saboo, B | 1 |
| Devaramani, S | 1 |
| Vijaykumar, NB | 1 |
| Sharma, S | 1 |
| Agrawal, N | 1 |
| Mahesh, M | 1 |
| Kothari, K | 1 |
| Charan, J | 1 |
| Belsey, JD | 1 |
| Rainsford, KD | 1 |
| Parke, AL | 1 |
| Clifford-Rashotte, M | 1 |
| Kean, WF | 1 |
| Luthra, A | 2 |
| Misra, A | 2 |
| Mudur, G | 1 |
| Jain, M | 1 |
| Jani, RH | 1 |
| Ozen, G | 1 |
| Pedro, S | 1 |
| Holmqvist, ME | 1 |
| Avery, M | 1 |
| Wolfe, F | 1 |
| Michaud, K | 1 |
| Goucha, S | 1 |
| Khaled, A | 1 |
| Kharfi, M | 1 |
| Fazaa, B | 1 |
| Zermani, R | 1 |
| Ben Jilani, S | 1 |
| Kamoun, MR | 1 |
| Bili, A | 1 |
| Sartorius, JA | 1 |
| Kirchner, HL | 1 |
| Morris, SJ | 1 |
| Ledwich, LJ | 1 |
| Antohe, JL | 1 |
| Dancea, S | 1 |
| Newman, ED | 1 |
| Wasko, MC | 1 |
| Bongartz, T | 1 |
| Kudva, Y | 1 |
| Fai, D | 1 |
| Romano, I | 1 |
| Cassano, N | 1 |
| Vena, GA | 1 |
| Shojania, K | 1 |
| Koehler, BE | 1 |
| Elliott, T | 1 |
| Shimoni, A | 1 |
| Hershcovici, T | 1 |
| Mekhmandarov, S | 1 |
| Maor-Kendler, Y | 1 |
| Beigel, Y | 1 |
| Gerstein, HC | 1 |
| Thorpe, KE | 1 |
| Taylor, DW | 1 |
| Haynes, RB | 1 |
| Quatraro, A | 1 |
| Consoli, G | 1 |
| Magno, M | 1 |
| Caretta, F | 1 |
| Nardozza, A | 1 |
| Ceriello, A | 1 |
| Giugliano, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.[NCT02874287] | Phase 4 | 35 participants (Actual) | Interventional | 2017-10-08 | Completed | ||
| Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis[NCT01132118] | Phase 3 | 30 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults[NCT05808231] | 100 participants (Anticipated) | Interventional | 2021-04-26 | Recruiting | |||
| Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa[NCT03275870] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2017-09-28 | Completed | ||
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| The Effect of Berberine on the Secretion of Incretin in Normal Man[NCT05947370] | Early Phase 1 | 16 participants (Actual) | Interventional | 2022-10-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 58.1 | 59.4 | 1.3 |
| Placebo | 58.1 | 60.3 | 2.2 |
HOMA-B = (360 x Insulin)/(Glucose - 63) (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (mIU x dL)/(L x mg) (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 116.5 | 110.8 | -5.8 |
| Placebo | 116.5 | 109.7 | -6.8 |
"We will examine the effect of HCQ on HOMA-IR during the active treatment phase compared with placebo phase.~HOMA-IR = (Glucose x insulin)/405" (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (mg x mIU)/(dL*L) (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 2.0 | 1.7 | -0.3 |
| Placebo | 2.0 | 1.6 | -0.42 |
"We will examine the effect of HCQ on the Matsuda Insulin Sensitivity Index (ISI) during the active treatment phase compared with placebo phase.~ISI is based on insulin and glucose levels in a fasting state during an oral glucose tolerance test (OGTT) and is calculated as follows:~ISI (Matsuda) = 10000/√ G0 X I0 X Gmean X Imean~G0 - fasting plasma glucose (mg/dL) I0 - fasting plasma insulin (mIU/L) Gmean - mean plasma glucose during OGTT (mg/dL) Imean - mean plasma insulin during OGTT (mIU/L)" (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (dL x L)/(mg x mIU) (Mean) | ||
|---|---|---|---|
| Baseline | Period Value | Change | |
| Hydroxychloroquine | 7.7 | 8.1 | 0.4 |
| Placebo | 7.7 | 7.8 | 0.14 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 114.1 | 101.7 | -12.4 |
| Placebo | 114.1 | 109.9 | -4.2 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 192.4 | 179.7 | -12.7 |
| Placebo | 192.4 | 189.4 | -3.0 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 100.6 | 92.4 | -8.2 |
| Placebo | 100.6 | 95.6 | -5.0 |
Comparison of baseline and post-treatment Sartorius severity scoring Sartorius scoring: minimum 0, no maximum, higher scores mean a worse outcome (NCT03275870)
Timeframe: 6 months
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline sartorius score | 6 month sartorius score | |
| Hydroxychloroquine Treatment | 23.3 | 17.7 |
Comparison of baseline and post-treatment self-reported quality of life Dermatology Life Quality Index score: minimum 0, maximum 30. higher scores mean worse outcome. (NCT03275870)
Timeframe: 6 months
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline DLQI score | 6 month DLQI score | |
| Hydroxychloroquine Treatment | 14.7 | 6 |
5 reviews available for hydroxychloroquine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Colchicine; Diabetes Mellitus, | 2022 |
Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2023 |
Potential Effect of Hydroxychloroquine in Diabetes Mellitus: A Systematic Review on Preclinical and Clinical Trial Studies.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hy | 2020 |
Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic.
Topics: Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Diabetes Complications; | 2020 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diabetes Mellitus, Type 2; Dose-R | 2015 |
7 trials available for hydroxychloroquine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study.
Topics: Adult; Aged; Antimalarials; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated H | 2020 |
Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antimalarials; Biomarkers; Diabetes Mellitus, Type 2; | 2021 |
The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial.
Topics: Adult; Diabetes Mellitus, Type 2; Humans; Hydroxychloroquine; Inflammation; Insulin; Insulin Resista | 2021 |
Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Over Studies; Diabetes Mellitus, Type 2; Do | 2014 |
Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Over Studies; Diabetes Mellitus, Type 2; Do | 2014 |
Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Over Studies; Diabetes Mellitus, Type 2; Do | 2014 |
Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Over Studies; Diabetes Mellitus, Type 2; Do | 2014 |
Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2014 |
The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial.
Topics: Body Mass Index; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination | 2002 |
Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug?
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Human | 1990 |
27 other studies available for hydroxychloroquine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effects of Hydroxychloroquine on Progression of Diabetic Retinopathy in Subjects with Rheumatoid Arthritis and Type 2 Diabetes Mellitus.
Topics: Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; Hydroxychloroquine; | 2022 |
Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19.
Topics: Animals; Chloroquine; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2022 |
Sjögren syndrome is a hidden contributor of macrovascular and microvascular complications in patients with type 2 diabetes.
Topics: Aspirin; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hydroxychlo | 2022 |
Hydroxychloroquine in diabetes and dyslipidaemia: primum non nocere.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Enzyme Inhibitors; Human | 2020 |
Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hydroxychloroquin | 2019 |
Coronavirus disease 2019 in pregnancy: early lessons.
Topics: Acute Kidney Injury; Adult; Anesthesia, General; Anti-Bacterial Agents; Antihypertensive Agents; Azi | 2020 |
Idiopathic nonhistaminergic acquired angioedema in a patient with coronavirus disease 2019.
Topics: Adenosine Monophosphate; Adult; Alanine; Ampicillin; Angioedema; Betacoronavirus; Coronavirus Infect | 2020 |
Description of 3 patients with myasthenia gravis and COVID-19.
Topics: Adult; Aged; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
An infection-oriented approach for thoracic endovascular aortic repair in a SARS-CoV-2 positive patient. A case report.
Topics: Anesthesia, Local; Antibiotic Prophylaxis; Anticoagulants; Antiviral Agents; Aortic Aneurysm, Thorac | 2020 |
First-time Diabetic Ketoacidosis in Type 2 Diabetics With Covid-19 Infection: A Novel Case Series.
Topics: Anti-Bacterial Agents; COVID-19; Crystalloid Solutions; Diabetes Mellitus, Type 2; Diabetic Ketoacid | 2020 |
Relationship of Hydroxychloroquine and Ophthalmic Complications in Patients with Type 2 Diabetes in Taiwan.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Humans; Hydroxychloroquine; | 2021 |
Treatment of subcutaneous sarcoidosis with hydroxychloroquine: report of 2 cases.
Topics: Adrenal Cortex Hormones; Biopsy; Contraindications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Ty | 2014 |
Re: Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin 2014;30:1257-66.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hydroxychloroquine; Hypoglycemic Agents; Male; Thiazolidi | 2015 |
Re: Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin 2014;30:1257-66.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hydroxychloroquine; Hypoglycemic Agents; Male; Thiazolidi | 2015 |
Re: Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin 2014;30:1257-66.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hydroxychloroquine; Hypoglycemic Agents; Male; Thiazolidi | 2015 |
The marketing of unproven drugs for diabetes and dyslipidaemia in India.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2015 |
Indian endocrinologists start debate on diabetes drug.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2015 |
Drug approvals in India.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2016 |
Drug approvals in India.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2016 |
Drug approvals in India - Authors' reply.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2016 |
Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
Topics: Abatacept; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Drug Therap | 2017 |
Granuloma annulare.
Topics: Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Adult; Anti-Infective Agents; Antirh | 2008 |
Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Diabetes Mellitus, Type 2; Female | 2011 |
Can treatment of chronic inflammatory diseases reduce the risk of diabetes mellitus?
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Hu | 2011 |
Cutaneous lupus erythematosus of the scalp treated with methyl-aminolevulinate photodynamic therapy: a case report.
Topics: Adrenal Cortex Hormones; Aged, 80 and over; Aminolevulinic Acid; Comorbidity; Contraindications; Dia | 2012 |
Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis.
Topics: Aged; Antirheumatic Agents; Arthritis; Diabetes Mellitus, Type 2; Humans; Hydroxychloroquine; Hypogl | 1999 |
Skeletal sarcoidosis: successful treatment with hydroxychloroquine.
Topics: Antimalarials; Bone Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hydroxychloroquine; Middle | 2000 |